KoreaBIO conducted its Q2 and H1 2026 Trend Survey, examining key business trends among listed bio & healthcare companies in Korea!
H1 2026 revenue increased by 13.1% YoY, with pharmaceuticals up 12.5% and medical devices up 18.7%. Exports also grew 12.6% YoY, reflecting continued growth across both domestic and overseas markets.
In Q2, revenue increased 10.4% YoY, while R&D expenditure rose 18.9% YoY, showing continued investment in R&D alongside revenue growth.
